Printer Friendly

SYSTEMIX REPORTS THE PUBLICATION OF TWO MAJOR SCIENTIFIC ARTICLES

 SYSTEMIX REPORTS THE PUBLICATION OF TWO MAJOR SCIENTIFIC ARTICLES
 PALO ALTO, Calif., April 2 /PRNewswire/ -- Researchers at SyStemix, Inc. (NASDAQ: STMX) today announced the publication of two articles in the April 1 editions of two prestigious scientific journals.
 In the first paper, published yesterday in Proceedings of the National Academy of Sciences, scientists found putative pluripotent stem cells (human fetal hematopoietic stem cells -- HSC's) engrafted into SyStemix's proprietary SCID-hu mouse produces human B and T cells, monocytes and granulocytes. In culture, this system can additionally produce red blood cells. The results indicate that these cells create a full spectrum of blood and immune cells. The results have wide implications in the treatment of cancer, AIDS, gene therapy and organ transplantation.
 The authors of the report are Charles Baum, M.D., Ph.D; Irving I. Weissman, M.D.; Ann S. Tsukamoto, Ph.D; Ann-Marie Buckle, Ph.D.; and Bruno Peault, Ph.D.
 SyStemix has received a U.S. Patent (no. 5,061,620) for the separation of human hematopoietic stem cells from bone marrow and for their cellular composition.
 In a related paper appearing in the journal, Blood, SyStemix researchers found that the company's SCID-hu mouse technology was able to sustain human blood formation, in vivo, for 20 weeks. Using the SCID-hu mouse, scientists were able to replicate all of the human cellular interactions involved in human blood formation. This would enable scientists to create, in vivo, a wide variety of physiological and pathological conditions found in human bone marrow. This model could be used to study growth factors (cytokines and interleukins). By injecting the SCID-hu mouse with human erythropoitin (EPO), SyStemix scientists were able to demonstrate the stimulation of human red blood cell formation in human bone implants.
 The test results may identify various potential therapeutic agents such as antivirals, chemotherapeutics and cytokines. This could be useful in studying various kinds of cancer and infectious diseases.
 The second report's authors are Seishi Kyoizumi, Ph.D.; Baum; Hideto Kaneshima, M.D., Ph.D.; Joseph (Mike) McCune, M.D., Ph.D.; Edwin Yee; and Reiko Namikawa, M.D., Ph.D.
 "The publication of these articles demonstrates the company's abilities to use its proprietary SCID-hu mouse technology to expedite the drug discovery and drug development process," said Dr. Linda Sonntag, president and CEO of SyStemix. "SyStemix will use this model to accelerate the development of its products, namely, stem cell growth factors, megakaryocytes stimulating factor and gene therapy for the treatment of HIV, among others," said Sonntag.
 SyStemix, Inc. is primarily engaged in the development of cellular processes and products based on human hematopoietic stem cells, human megakaryocytes and megakaryocyte progenitors. The company is based in Palo Alto, Calif.
 -0- 4/2/92
 /CONTACT: Linda Sonntag, president and CEO of SyStemix, 415-856-4901, ext. 218, or Anthony J. Russo of Noonan/Russo Communications, 212-979-9180, for SyStemix/
 (STMX) CO: SyStemix, Inc. ST: California IN: MTC SU:


TQ-OS -- NY026 -- 4320 04/02/92 11:15 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 2, 1992
Words:490
Previous Article:PEACH BOTTOM CO-OWNERS REACH SETTLEMENT
Next Article:VANTAGE POINT ENERGY INC. ANNOUNCES RECORD 1991 FINANCIAL RESULTS
Topics:


Related Articles
SANDOZ LTD. TO ACQUIRE 60 PERCENT OF SYSTEMIX COMMON STOCK
SYSTEMIX REPORTS THE PUBLICATION OF TWO MAJOR SCIENTIFIC ARTICLES
SYSTEMIX DISCOVERY OF PLURIPOTENT STEM CELLS NAMED ONE TOP 10 MEDICAL ADVANCES OF 1992
SYSTEMIX ENTERS JOINT VENTURE WITH SANDOZ FOR GENE THERAPY AGAINST HIV
SYSTEMIX REPORTS HIV FINDING IN 'NATURE'
SYSTEMIX REPORTS SECOND QUARTER AND SIX MONTHS RESULTS
SYSTEMIX REPORTS SECOND QUARTER AND SIX MONTH RESULTS
SYSTEMIX PRESIDENT/CEO RESIGNS
SYSTEMIX' DISEASE-FREE STEM CELL TRANSPLANTS MAY CONTRIBUTE TO IMMUNE SYSTEM RECOVERY
Novartis to Optimize Cell and Gene Therapy R&D

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters